During the past 12 months there have been clinically important advances in intravenous nutrition and adjunctive therapies.
Introduction
It has become axiomatic that intravenous nutrition (IVN) is inferior to enteral nutrition. Certainly strenuous efforts are now made to avoid IVN whenever the gut is functional, and usually correctly so. Various arguments are produced to support this including potential adverse effects on gut integrity as well as the range of welldocumented complications. IVN can clearly be improved, and this year's literature review indicates a number of ways in which this can or might be achieved.
Altered physiology in the parenterally fed
New Swedish data demonstrate that an apparent increase in number and decrease in function of rat submucous and myenteric neurones can be attributed to associated morphometric changes [1 ] . The authors conclude that thickening of the submucosa and reduced intestinal circumference lead to 'condensation' of neurones with only minor alteration in selected neurotransmitters. Alternative explanations remain possible given that no hypothesis yet satisfactorily explains the morphological findings.
The same group has added to the burgeoning literature on ghrelin, the upper gastrointestinal hormone closely associated with appetite and weight regulation. Ghrelin was measured in blood and gastric mucosa in rats on exclusive IVN [2 ] . In comparison to fasted animals, which had high ghrelin levels, the exclusive IVN rats proved barely distinguishable from those on normal diet, pointing strongly away from the premise that the presence or absence of food in the gut is its main determinant. It is suggested that circulating lipid may suppress ghrelin in the exclusive IVN animal.
Leptin has been examined in rats on exclusive IVN in the UK. Its effects on cell proliferation and crypt fission were explored, but few major changes were found [3 ] . There was the expected slightly lower body mass in leptintreated animals, but no evidence for reversal of the IVN-induced reduction in proliferation. Different effects on crypt fission were seen at different sites in the gut, the significance of which remains uncertain.
Glucagon-like peptide 2
Glucagon-like peptide 2 (GLP-2) has received a lot of attention. Secreted from intestinal L cells and with receptors mainly in the ileum this trophic factor has been an obvious target for those interested in intestinal failure.
Our own work has shown a substantial effect of GLP-2 on small bowel growth in the exclusive IVN rat (to some extent synergistic with epidermal growth factor) [4 ] . Parallel work from Texas using neonatal piglets shows that intravenous GLP-2 increases proximal small intestine tissue perfusion and portal venous blood flow [5 ] . This group has also demonstrated that GLP-2 helps to maintain intestinal structure, and optimise hexose and lactose handling [6 ] . The villi were longer and the in-vivo absorption of glucose and galactose better than in piglets on IVN alone, suggesting that the effects are of functional significance.
GLP-2 itself is not, however, ideal for pharmacological use as it has a very short half-life, being rapidly metabolized by dipeptidyl peptidase IV (DPP4). A group from Barcelona wondered if differences in endogenous DPP4 might account for differing degrees of intestinal adaptation to apparently similar resectional loss [7 ] , but this proved not to be the case, all patients having essentially normal values. It is therefore fortunate that a single amino acid substitution in GLP-2 appears to leave full activity but with resistance to DPP4. This modified GLP-2teduglutide -is now undergoing clinical trial.
A 21-day placebo-controlled study of subcutaneous teduglutide, (0.03-0.15 mg/kg/day), was performed in 16 patients with short bowel syndrome [8 ] . Wet weight absorption, urine volume, and urinary sodium excretion were increased, and intestinal losses were diminished. There were improvements in small bowel villous integrity, with no measurable changes in colonic biopsies. Predictions of daily benefits in the region of 500 kcal increased absorption and 750 ml improvement in fluid balance have prompted a more definitive controlled trial now in progress.
Cholestasis
Progressive cholestasis from IVN is relatively rare so long as prolonged high doses of lipid are avoided, but when it occurs, it remains one of the most serious complications. Several of the heavy metals, including copper, have been implicated in its pathogenesis. A group from Vermont performed quantitative hepatic copper studies on a cohort of 28 patients considered to have IVN-related liver disease [9 ] . Almost a third of the patients had liver coppers high enough otherwise to make a diagnosis of Wilson's disease, and levels were above normal in 25 (89%). There was no apparent correlation with duration of IVN or (surprisingly) with serum copper, and the authors felt that iatrogenic copper overload was an unlikely explanation.
There has been speculation that supplementary taurine might, via increased tauro-conjugation of bile acids, limit IVN-associated cholestasis, and a Spanish study examines the addition of taurine to a standard IVN admixture in rabbits [10 ] . Interestingly the animals on supplementary taurine had lower serum levels than those on conventional IVN. There was, however, a striking (> 50%) increase in excretion of bile acids. It would be unwarranted to extrapolate too much to the human situation given the dosing regimes and the short duration of this study (10 days), but the final autopsies of the control animals revealed overt steatosis, dilated bile canaliculi and multiple bile plugs, compared with much milder steatosis alone in the taurine treated rabbits.
Gall stone formation in IVN patients may not be closely associated with the risk of cholestasis but this is certainly an important clinical issue [> 50% of home parenteral nutrition (HPN) patients have stones]. Clinicians from Michigan tried to reduce this risk by the use of cholecystokinin in a controlled trial of 38 human neonates fed for a mean of 33 days [11 ] . Evaluation was not performed until at least 2 years after the treatment period. By this time 10% of the children had stones and there had been no advantage from cholecystokinin (three versus one placebo child with stones; not significant).
Other additions to intravenous nutrition admixtures
Supraphysiological doses of ascorbic acid can be helpful in the stabilization of IVN admixtures, as well as compensating for vitamin degradation with more prolonged storage. Higher daily doses are also now advised by the American Food and Drug Administration. Recognizing the potential for its metabolism to oxalate, the safety of this approach has been assessed at the Mayo Clinic. Thirteen IVN patients on the new 200 mg daily intravenous dose had their status compared with that on the previous 100 mg dose [12 ] . No apparent changes in oral vitamin C or oxalate had occurred, but there was a substantial increase in urinary oxalate excretion (0.34-0.44 mmol/day). Urinary oxalate stones have been a concern in short bowel patients with intact colons. Extra scrutiny appears deserved.
Supplementary glutamine now has a strong track record in intensive care and aggressive chemotherapy, mainly through reduction in serious sepsis, but data to support its more general use in IVN practice have been lacking. It seems only to help in the very sickest patients who are simultaneously deprived of enteral glutamine. A German collaborative group has now evaluated its isonitrogenous inclusion in IVN for patients with inflammatory bowel disease, and it is perhaps unsurprising that it was without apparent benefit [13 ] .
Glucose and insulin
Glucose provision to patients on IVN has been limited by calculated oxidative capacity and a guideline limit of 4 mg/kg/min, or a maximal IVN glucose concentration of 15%, with the recognition that overload will promote net lipogenesis. Schloerb [14 ] repeated a survey of glucose use, this time in 629 patients in 44 hospitals. Nearly 16% of patients were receiving glucose infusion rates above 4 mg/kg/min, and 61% of regimes had glucose concentrations above 15%. The clinical consequences of these findings are uncertain.
Prompted by the paradigm-changing results from Belgium on the value of tight glucose homeostasis in the intensive care unit setting, a Swedish group has explored this in the particular context of six trauma patients on IVN [15 ] . Endogenous glucose production and whole-body glucose disposal were 30% higher in unfed patients than in healthy controls. Their glucose production moved toward normal during IVN but the reductions were much less than in controls placed on IVN. Glucose disposal, however, did not change. Normoglycaemia was achievable in all patients (with higher doses of insulin than in controls) and it appears that the suppression of endogenous production is, in this context, both the principal challenge and a feasible goal.
Developing this theme a French group has explored the optimization of glucose : lipid ratio in 47 critically ill patients over a 7-day timescale [16 ] . Efficacy was judged from nitrogen balance, urinary methylhistidine : creatinine ratio, and transthyretin, and tolerance by blood glucose and hepatic biochemistry. It was possible to assess only a limited range of options in a single study, but the overall results favoured a 50 : 50 ratio over an isocaloric regime containing more glucose. Maintenance of euglycaemia and normal hepatic function were better, albeit at the cost of slightly less nitrogen sparing. This could reasonably be adopted into intensive care practice (with the caution that this would provide dangerously excessive amounts of lipid on a long-term basis in patients going forward to HPN).
Lipids
Patients on HPN are at risk of hepatic dysfunction and complications from thrombosis and infection. Animal data suggest that an alteration in lipid provision from polyunsaturates towards mono-unsaturates could be beneficial, and the availability of a lipid emulsion rich in olive oil prompted my group to study its effects in a 6-month open study of HPN patients in comparison with the 6-month periods before and after the intervention [17 ] . Limitations of the study design preclude emphatic conclusions but it appeared that thrombotic episodes were less likely, and in-patient days fewer during the treatment period.
In Madrid the same olive oil-based lipid was evaluated over 7 days in the severely burned, in comparison with a medium-chain triglyceride-enriched emulsion [18 ] . There were significantly fewer abnormalities of liver function in the olive oil group without any evidence of hazard, but with no differences in overall mortality or other major morbidity.
German authors studied another new lipid preparation which was also designed to present mono-unsaturates, in this case together with additional n-3 fatty acids [19 ] . In comparison with a standard soya-based lipid emulsion in 33 postoperative patients the new product was associated with reduced hospital stay -a remarkable 7-day difference [13 days (AE 2.0) versus 20 days (AE 10.0)] -and a range of improvements in pertinent laboratory markers including leukotriene levels.
Clinical practice
Much of the nutrition literature expounds the virtues of enteral over parenteral nutrition, but in the patient with a high output proximal fistula this has usually been thought impracticable and inappropriate. The Salford group demonstrates that even in these challenging cases it is possible to reduce need for IVN by direct enteral feeding via the fistula itself [20 ] . So long as there is mucocutaneous continuity they now feel confident using a modified gastrostomy device, and were able to withdraw IVN in 11 of 12 patients previously considered dependent on parenteral nutrition. This proved safe and good nutritional status was maintained until the time of intentionally deferred reconstructional surgery at a median of 155 days. This so-called fistuloclysis is not without its problems, however, and will not suit every eligible patient.
Despite best efforts some HPN patients have recurrent line infections. This has been tackled in Toronto by a daily line flush with the antimicrobial agent taurolidine in seven of their recidivists [21 ] . A pre-treatment infection rate of 10.8 infections per 1000 catheter days fell to 0.8, but the open design of the study makes it difficult to be sure how much of this impressive effect was the direct result of the intervention.
Loss of venous access is, internationally, increasingly a strong indication for intestinal transplantation in HPN patients, but alternatives are nicely outlined by the Boston radiological service in 12 patients with extensive central venous occlusion [22 ] . They used a combination of sharp-needle recanalization, venous stenting and 'extra-anatomic' access to the central venous system. Access was achieved in all without mortality or irreversible morbidity. Venous patency was then preserved to a mean follow-up of 20 months in all but two patients. These techniques can also be used as a bridge to surgery in patients in whom even transplantation is contraindicated because of their parlous vascular access.
Home parenteral nutrition in the cancer patient?
The provision of HPN to the terminally ill raises ethical and emotional issues that affect its utilization such that it is much rarer in northern Europe than in (say) Italy or the USA. A small collection of recent publications helps to introduce some objective evidence into the continuing debate.
From Taiwan there comes confirmation that immune function is impaired in (early) colorectal cancer and that this may be ameliorated by the provision of IVN [23 ] . The possibility that this is disadvantageous from an oncological viewpoint is passed over, but that aspect is much less important in the patient receiving palliative care.
A regional audit in Canada considered patients with metastatic disease who, over a 6-year period, had been referred for HPN, and nine of whom had inoperable intestinal obstruction [24 ] . Six of the nine survived for more than 2 months and one to more than 14 months. Only one had important related complications (thrombosis and line sepsis) and review revealed no obvious determinants of prognosis present at the time of commencing HPN. It seems reasonable to have a low threshold for accepting such patients into HPN programmes if overall status is otherwise good.
The Mayo Clinic has also engaged in retrospective review considering all adults with incurable cancer treated with HPN between 1979 and 1999 [25 ] . There is an obvious problem with such analyses as they exclude potentially relevant patients who were excluded (for whatever reason) from the programme, but the results in those included are impressive. Over 50 patients were treated for a wide range of different malignancies, intestinal obstruction contributing to the decision to feed intravenously in 20. Death occurred a median of 5 months after starting IVN and 16 patients survived for over a year. As in the Canadian study there did not seem to be an inopportune frequency of complications, nor were there identifiable clinical prognostic markers from the time of commencement. As the authors conclude 'judicious use' of HPN is acceptable and can be associated with worthwhile medium-term survival. How this judgment might be quantified and converted into generalizable guidelines remains a question.
Nutrition teams
Hospitals with nutrition teams are generally proud and appreciative of the contributions made, but those without and wishing to establish them tend to find major financial obstacles in their way. Efforts to provide objective (and preferably cost-effective) evidence in their favour are therefore especially welcomed. A surgically-run team in Virginia provides clear evidence for improved practice and a demonstrable reduction in the inappropriate use of IVN: from 32% to 8% of all prescriptions in one hospital over a 22-month period [26 ] . Unfortunately, from the purely financial perspective, their overall use of IVN rose slightly during the study period. In England the unique contribution of the nutrition specialist nurse has again been shown to be beneficial [27 ] . In-hospital catheterrelated sepsis rates fell from 52% to 2.3% in the 4 years after the appointment of a nutrition nurse. It is improbable that there were no other important changes over this time (including potential differences in reporting of line infections) and a retrospective analysis such as this must be treated with some caution. Nonetheless this report is consistent with the prior literature, and here is costed to the effect that the salary of the nurse is almost outweighed by the direct savings from wasted catheters, feed and operating time. The obvious but indirect benefits to the patients form a crucial additional factor in favour of properly supported nutrition teams.
The final word on this topic should correctly go to a metaanalysis published in mid 2004 [28 ] . Eleven primary studies were considered eligible for review although only four of these had concurrent controls. There is clear evidence that mechanical complications of IVN are reduced by the presence of a nutrition team, but conclusions favouring reductions in catheter-related sepsis, metabolic and electrolyte disturbances, are less certain. Total costs were elicited from only two primary studies, but the review team considered that there was evidence for cost-effectiveness and that financial savings were likely to follow the introduction of multidisciplinary teams in the hospital setting.
Conclusion
It appears that we can reasonably conclude that GLP-2 has IVN sparing effects, and that lipid emulsions based less on soy-bean oil are safe, effective, and possibly advantageous. Euglycaemia is valuable in IVN practice at all times, but excess vitamin C may be detrimental. Long-term IVN in cancer patients can be justified in selected patients. Further supportive data in favour of hospital nutrition teams indicate probable cost-effectiveness.
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